Therapeutic efficacy of a tuberculosis DNA vaccine encoding heat shock protein 65 of Mycobacterium tuberculosis and the human interleukin 2 fusion gene

Tuberculosis

Volumn 89, Issue 1, 2009, Pages 54-61

  Changhong, Shi ^a   Hai, Zhang ^a   Limei, Wang ^a   Jiaze, An ^b   Li, Xi ^a   Tingfen, Zhang ^a   Zhikai, Xu ^a   Yong, Zhao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

DNA; HSP65; IL 2; Mycobacterium tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 65 DNA VACCINE; HEAT SHOCK PROTEIN 65 INTERLEUKIN 2 DNA VACCINE; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 2; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSION GENE; GENE EXPRESSION; GENE SEQUENCE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; LUNG TUBERCULOSIS; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TREATMENT RESPONSE;

ANIMALS; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHAPERONINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; HUMANS; INTERLEUKIN-2; LUNG; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RANDOM ALLOCATION; RECOMBINANT FUSION PROTEINS; SPLEEN; TH1 CELLS; TH2 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, DNA;

EID: 58149133629     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2008.09.005     Document Type: Article

References (33)

1. World Health Organization. Tuberculosis-fact sheet no.104. Available from: (2002).
2. Telenti, Amalio, Iseman, and Michael. Drug-resistant tuberculosis: what do we do now. Drug 59 (2000) 171-179
3. Cain K.P., Kanara N., Laserson K.F., Vannarith C., Sameourn K., Samnang K., et al. The epidemiology of HIV-associated tuberculosis in rural Cambodia. Int J Tuberc Lung Dis 11 (2007) 1008-1013
4. Zumla A., Malon P., Henderson J., and Grange J. Impact of HIV on tuberculosis. Postgrad Med J 76 (2000) 259-268
5. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346 (1995) 1339-1345
6. Roy E., Lowrie D.B., and Jolles S.R. Current strategies in TB immunotherapy. Curr Mol Med 7 (2007) 373-386
7. Cox H.S., Morrow M., and Deutschmann P.W. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336 (2008) 484-487
8. Lowrie D.B., Silva C.L., Colston M.J., Ragno S., and Tascon R.E. Protection against tuberculosis by a plasmid DNA vaccine. Vaccine 15 (1997) 834-838
9. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 (1999) 269-271
10. Kim J.J., Yang J.S., Montaner L., Lee D.J., Chalian A.A., and Weiner D.B. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J Interferon Cytokine Res 20 (2000) 311-319
11. Baek K.M., Ko S.Y., Lee M., Lee J.S., Kim J.O., Ko H.J., et al. Comparative analysis of effects of cytokine gene adjuvants on DNA vaccination against Mycobacterium tuberculosis heat shock protein 65. Vaccine 21 (2003) 3684-3689
12. Barouch D.H., Letvin N.L., and Seder R.A. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202 (2004) 266-274
13. Hong-Xuan H., Lei C., Cheng-Min W., Kai Z., Yi T., Xi-Ming Q., et al. Expression of the recombinant fusion protein CP15-23 of Cryptosporidium parvum and its protective test. J Nanosci Nanotechnol 5 (2005) 1292-1296
14. Huang Y.S., Chen Z., Chen Y.Q., Ma G.C., Shan J.F., Liu W., et al. Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J Pept Sci 12 (2007) [epub ahead of print]
15. Matteelli A., Migliori G.B., Cirillo D., Centis R., Girard E., and Raviglion M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 5 (2007) 857-871
16. Yu D.H., Hu X.D., and Cai H. Efficient tuberculosis treatment in mice using chemotherapy and immunotherapy with the combined DNA vaccine encoding Ag85B, MPT-64 and MPT-83. Gene Ther 9 (2008) 652-659
17. Zhu D., Jiang S., and Luo X. Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. Vaccine 23 (2005) 4619-4624
18. Silva C.L., Bonato V.L., Coelho-Castelo A.A., De Souza A.O., Santos S.A., Lima K.M., et al. Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice. Gene Ther 12 (2005) 281-287
19. Derrick S.C., Repique C., Snoy P., Yang A.L., and Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 72 (2004) 1685-1692
20. Berrington W.R., and Hawn T.R. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?. Immunol Rev 219 (2007) 167-186
21. Lazarevic V., and Flynn J. CD8+ T cells in tuberculosis. Am J Respir Crit Care Med 166 (2002) 1116-1121
22. Serbina N.V., Lazarevic V., and Flynn J.L. CD4(+) T cells are required for the development of cytotoxic CD8(+) T cells during Mycobacterium tuberculosis infection. J Immunol 167 (2001) 6991-7000
23. Tascon R.E., Colston M.J., Ragno S., Stavropoulos E., Gregory D., and Lowrie D.B. Vaccination against tuberculosis by DNA injection. Nat Med 2 (1996) 888-889
24. Taylor J.L., Ordway D.J., Troudt J., Gonzalez-Juarrero M., Basaraba R.J., and Orme I.M. Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA. Infect Immun 73 (2005) 5189-5193
25. Kjeldsen-Kragh J., Quayle A.J., Skalhegg B.S., Sioud M., and Forre O. Selective activation of resting human gamma delta T lymphocytes by interleukin-2. Eur J Immunol 23 (1993) 2092-2099
26. Johnson B.J., Bekker L.G., Rickman R., Brown S., Lesser M., Ress S., et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis 78 (1997) 195-203
27. Kamath A.T., Feng C.G., Macdonald M., Briscoe H., and Britton W.J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67 (1999) 1702-1707
28. Lima K.M., dos Santos S.A., Rodrigues Jr. J.M., and Silva C.L. Vaccine adjuvant: it makes the difference. Vaccine 22 (2004) 2374-2379
29. Zhang X., Divangahi M., Ngai P., Santosuosso M., Millar J., Zganiacz A., et al. Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene. Vaccine 25 (2007) 1342-1352
30. Wozniak T.M., Ryan A.A., Triccas J.A., and Britton W.J. Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. Infect Immun 74 (2006) 557-565
31. Goncalves E.D., Bonato V.L., da Fonseca D.M., Soares E.G., Brandao I.T., Soares A.P., et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther 22 (2007) 1-14
32. Xing Z., Santosuosso M., McCormick S., Yang T.C., Millar J., Hitt M., et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther 5 (2005) 485-492
33. Taylor J.L., Turner O.C., Basaraba R.J., Belisle J.T., Huygen K., and Orme I.M. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect Immun 71 (2003) 2192-2198